New Ovarian Cancer Treatment Showed Promise in Trial
A new antibody-drug conjugate produced objective response rates in patients with platinum-resistant ovarian cancer.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you believe experimental cancer drug treatments are likely to outperform standard current medical options?
OnCusp Therapeutics reported positive Phase 1b clinical trial results for CUSP06, a new therapy for patients with platinum-resistant ovarian cancer. The drug showed significant response rates in a study of 86 patients who had exhausted multiple prior treatment options.
Why it matters
Patients with platinum-resistant ovarian cancer face limited treatment options, making the development of new therapeutic classes a critical priority for clinical care. This trial provides early evidence of the potential impact of CUSP06 for a population that has already received extensive prior therapy.
In a Phase 1b trial of 86 pre-treated ovarian cancer patients, those in the 4.0 mg/kg cohort achieved a 62% objective response rate. Preliminary results also showed a 53% response rate among patients previously treated with mirvetuximab soravtansine.
The players
OnCusp Therapeutics
A Princeton-based company focused on developing targeted cancer therapies.
Multitude Therapeutics
The original developer of the CUSP06 platform prior to licensing it in 2022.
The details
CUSP06 is an antibody-drug conjugate designed to target CDH6. It functions by using a protease-cleavable linker to deliver an exatecan payload directly to cancer cells. The trial assessed four dose cohorts ranging from 3.6 mg/kg to 4.4 mg/kg to identify efficacy and safety, reporting a 1% incidence of pneumonitis and no reported ocular toxicity.
Timeline
2022: OnCusp Therapeutics obtained global development rights for CUSP06.
September 23, 2026: Data cutoff for the Phase 1b trial analysis occurred.
October 3, 2026: Researchers presented the Phase 1b data at the IGCS Annual Global Meeting.
October 5, 2026: The company publicly announced the trial results.
Health Landscape
This study contributes to the growing interest in antibody-drug conjugates as a potential alternative for patients who have developed resistance to standard platinum-based chemotherapy. It marks a departure from traditional treatment arcs by targeting CDH6 in patients who have failed multiple prior therapies.
Patients with platinum-resistant ovarian cancer should discuss these emerging trial results with their oncologist to determine if they meet the criteria for upcoming pivotal-stage research. It is important to monitor future clinical trial listings to stay informed about enrollment opportunities.
The takeaway
The development of new antibody-drug conjugates represents a potential shift in care for individuals facing treatment-resistant ovarian cancer. Patients should track the progress of ongoing clinical trials and have regular conversations with their physicians about new trial eligibility.
Further reading
For context on how emerging treatments are assessed, visit our Cancer section.
More information
View the current status of studies at Clinical trial registration information.
Live Poll
Do you believe experimental cancer drug treatments are likely to outperform standard current medical options?
